Osteoarthritis Injections: Real Side Effects, by Type
The documented side effects of corticosteroid, hyaluronic acid and PRP injections for knee osteoarthritis, sourced from peer-reviewed evidence.
This covers what's documented for corticosteroid, hyaluronic acid and platelet-rich plasma injections used in knee osteoarthritis, where the evidence is strong versus contested, and what that means for a hospital stocking these products.
What are the documented side effects of corticosteroid knee injections?
A systematic review found that commonly used corticosteroids, methylprednisolone, dexamethasone, hydrocortisone, betamethasone, prednisolone and triamcinolone, show dose-dependent deleterious effects on cartilage morphology, histology and viability in both laboratory and animal models. Beneficial effects in animal models were generally seen only at low cumulative doses, typically under 2–3 mg per dose or 8–12 mg cumulative.
Clinical cohort data adds a further concern. One PubMed-indexed study found intra-articular corticosteroid injections associated with an increased likelihood of subsequently requiring knee arthroplasty. Another found a transient but statistically significant greater rate of meniscal thickness loss and joint space narrowing in the year an injection was given, compared to controls. Pain relief itself is typically modest and short-lived, averaging roughly two to four weeks compared with saline in meta-analysis data.
Is there disagreement in the evidence on corticosteroid injections?
Yes, and it's worth being direct about it rather than smoothing it over. Some structural studies found no significant effect on cartilage volume itself despite the meniscal and joint-space findings, and modest short-term pain relief is well replicated across trials even as longer-term structural concern has grown.
The more cautionary literature includes at least one peer-reviewed commentary arguing that longer-term corticosteroid injection use "offers only harm" for knee osteoarthritis. That reflects a genuine, ongoing debate in the orthopaedic and rheumatology literature about repeat dosing specifically, not a settled consensus against single or occasional injections.
What are the documented side effects of hyaluronic acid injections?
Systematic reviews comparing intra-articular hyaluronic acid with saline over a median follow-up of about six months found no statistically significant difference in adverse events (42.4% versus 39.7%) or serious adverse events (1.8% versus 1.2%). Most reported reactions were limited to local injection-site pain and swelling.
Overall side-effect incidence for hyaluronic acid intra-articular injection is documented at under 3% across the literature. Acute pseudoseptic arthritis, a sterile inflammatory flare mimicking infection, is described as a very rare complication, and true septic arthritis following injection, while extremely uncommon, has been documented in individual case reports and can be life-threatening when it occurs.
How do the risk profiles compare between corticosteroid and hyaluronic acid injections?
The two most commonly used osteoarthritis injections carry different risk profiles entirely. Corticosteroids show a documented, dose-dependent cartilage effect and a possible link to higher later arthroplasty rates. Hyaluronic acid's adverse-event rate tracks close to saline, with local reaction as the main downside. The table below lines up the documented differences side by side.
| Injection type | Documented adverse events | Structural/cartilage concern | Typical pain-relief duration |
|---|---|---|---|
| Corticosteroid | Local reaction; dose-dependent cartilage change in lab studies | Cohort data links repeat use to meniscal thinning, joint-space loss, higher arthroplasty rates | ~2–4 weeks, modest effect size |
| Hyaluronic acid | Comparable to saline; rare pseudoseptic arthritis; very rare septic arthritis | No consistent structural harm signal in systematic review data | Weeks to months, varies by product and regimen |
| Platelet-rich plasma | Local reaction most common; infection risk tied to injection technique, not the product itself | Evidence base still developing; fewer long-term structural studies than the other two | Variable, actively studied |
What does the evidence say specifically about platelet-rich plasma injections?
Platelet-rich plasma (PRP) shows a different side-effect pattern again. Systematic reviews comparing PRP with corticosteroid injections generally report PRP performing comparably or better on pain and function at longer follow-up, with local injection-site reaction as the most commonly reported adverse event. The evidence base is younger and less standardised.
PRP's preparation methods, including platelet concentration and leukocyte content, vary considerably across studies and are not yet uniformly reported, which makes cross-trial comparison harder than for corticosteroid or hyaluronic acid data.
Infection risk with any intra-articular injection, PRP included, is a function of injection technique and sterile preparation rather than the injected substance itself, which is why procedural standards matter as much as product selection in a hospital setting.
What should a hospital pharmacy know about stocking these injections?
A hospital's choice of which osteoarthritis injectable to stock, and in what volume, should track its actual orthopaedic and rheumatology patient mix rather than defaulting to whichever product a single specialist prefers. Corticosteroid vials are inexpensive and widely available; hyaluronic acid products vary considerably by brand, molecular weight and regimen (single-shot versus multi-injection courses), which affects both cost and shelf turnover.
When a hospital's in-house pharmacy doesn't reliably stock the specific hyaluronic acid product or PRP kit a treating orthopaedic surgeon has selected for a patient, that patient often ends up sourcing it externally or the procedure gets rescheduled, breaking continuity between the consult and the treatment. A managed or in-house pharmacy stocked against the actual injection mix a hospital's orthopaedic department uses keeps that continuity intact and keeps the prescription and procedure revenue inside the hospital rather than sending the patient elsewhere. Medyzen's guides on managed hospital pharmacy services, prescription leakage and hospital revenue loss, and pharmacy inventory management for expiry and dead stock cover this stocking gap in more detail, including how to reorder a slower-moving, higher-cost injectable range without letting it sit as dead stock.
Sources
- 1The Effect of Intra-articular Corticosteroids on Articular Cartilage: A Systematic Review — PubMed, National Library of Medicine
- 2Intra-articular corticosteroid injections increase the risk of requiring knee arthroplasty — PubMed, National Library of Medicine
- 3Intra-articular corticosteroid knee injection induces a reduction in meniscal thickness with no treatment effect on cartilage volume — PMC, National Institutes of Health
- 4Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews — PMC, National Institutes of Health
- 5Efficacy and Safety of Intra-articular Platelet-Rich Plasma (PRP) Versus Corticosteroid Injections in the Treatment of Knee Osteoarthritis — PMC, National Institutes of Health
This article is for informational purposes and is not a substitute for professional medical advice. Injection choice and dosing schedule should be decided by a treating orthopaedic specialist based on individual patient assessment.
FAQ
Frequently asked questions
Peer-reviewed evidence shows dose-dependent cartilage effects in laboratory studies and cohort data linking repeat corticosteroid injections to meniscal thinning, joint-space narrowing and a higher subsequent rate of knee arthroplasty. Pain relief is real but modest and typically lasts only two to four weeks, so the risk-benefit balance is more favourable for occasional use than repeated dosing.
Systematic review data shows hyaluronic acid adverse-event rates statistically similar to saline, with no consistent structural cartilage harm signal, compared with corticosteroid data showing dose-dependent cartilage effects and a possible link to increased arthroplasty rates in cohort studies. Hyaluronic acid's most common downside is local injection-site reaction, occurring in well under 3% of cases.
Septic arthritis following any intra-articular injection, including hyaluronic acid, corticosteroid or PRP, is a documented but very rare complication, with individual case reports in the peer-reviewed literature. Infection risk relates primarily to injection technique and sterile preparation rather than the specific product used.
The peer-reviewed literature does not establish a universally agreed safe number; the evidence instead shows that dose-dependent cartilage effects and structural risk increase with repeat use, which is why some rheumatology and orthopaedic sources caution against frequent repeat dosing. This is a clinical decision for the treating specialist, not a fixed number.
Some systematic reviews find PRP performing comparably or better than corticosteroid injections on pain and function at longer follow-up, but the PRP evidence base is younger and less standardised across preparation methods, so results vary by study and by how the PRP itself was prepared.
Dr. Anurag SharmaMBBS, M.S. Orthopaedics
Consultant Orthopaedic Surgeon
Dr. Anurag Sharma is a Consultant Orthopaedic Surgeon specializing in Joint Replacement & Preservation and Sports Injury & Arthroscopy. He holds an M.S. in Orthopaedics from S.M.S. Medical College, Jaipur, a fellowship in Joint Replacement and Pelvi-acetabular Surgeries under Dr. Ramesh Sen, and an Executive Program in Public Health Policy, Leadership and Management from AIIMS Jodhpur.